biostudies-literaturePalandri FMinistero della Salutee70320https://www.ebi.ac.uk/biostudies/studies/S-EPMC12904337biostudies-literatureUnknown132(4)<h4>Background</h4>Cytopenia is a common complication in patients with myelofibrosis and may worsen during treatment with ruxolitinib.<h4>Methods</h4>The RUX-MF multicenter study evaluated 879 patients treated with ruxolitinib for at least 6 months, categorizing them into four groups based on the evolution of cytopenia: never cytopenic, treatment-emergent cytopenia, persistent cytopenia, and improved anemia.<h4>Results</h4>At baseline, 40.6% of patients presented with cytopenia, increasing to 57.8% after 6 months. Baseline cytopenia was associated with significantly reduced median overall survival (OS) compared to noncytopenic patients (3.7 vs. 6.7 years). Prognosis varied notably across groups: patients who remained noncytopenic had the median best OS (8.1 years), whereas those with persiCancerSurvival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.PMC12904337RC-2025-2797275Pugliese NBonifacio MCrugnola MScalzulli ECilloni DDuminuco AHeidel FHBenevolo GMartino BIurlo AIsidori ABreccia MPalandri FBosi CBeggiato ELemoli RMBranzanti FDedola AMorsia EBinotto GTieghi AFarina MPane FAbruzzese ECaocci GBocchia MSartor CPalumbo GACavazzini FTiribelli MCattaneo DElli EMfalseSurvival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.<h4>Background</h4>Cytopenia is a common complication in patients with myelofibrosis and may worsen during treatment with ruxolitinib.<h4>Methods</h4>The RUX-MF multicenter study evaluated 879 patients treated with ruxolitinib for at least 6 months, categorizing them into four groups based on the evolution of cytopenia: never cytopenic, treatment-emergent cytopenia, persistent cytopenia, and improved anemia.<h4>Results</h4>At baseline, 40.6% of patients presented with cytopenia, increasing to 57.8% after 6 months. Baseline cytopenia was associated with significantly reduced median overall survival (OS) compared to noncytopenic patients (3.7 vs. 6.7 years). Prognosis varied notably across groups: patients who remained noncytopenic had the median best OS (8.1 years), whereas those with persi2026-01-01T00:00:00Z2026 Feb2026-07-15T21:59:42.674Z2026-07-09T10:19:56.156ZS-EPMC129043374168652810.1002/cncr.70320